Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT), Substudies: MRI, Cognitive
Sponsor: The George Institute
Listed as NCT02699645, this PHASE3 trial focuses on Hypertension and Intracerebral Haemorrhage (ICH) and remains completed. Sponsored by The George Institute, it has been updated 22 times since 2017, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Study Description(click to expand)Intracerebral haemorrhage (ICH) is the most serious and least treatable form of stroke, accounting for at least 10% of the 20 million new strokes that occur globally each year. Survivors of ICH are at high risk of recurrent ICH and other serious cardiovascular events.
While there is strong evidence that this risk can be reduced by lowering the blood pressure (BP) of patients after ICH, many patients with ICH do not receive BP-lowering treatment long-term unless BP levels are particularly high, and many do not receive BP combination therapy.
The aim of this study is to assess the safety and efficacy of a combination of fixed low-dose generic BP lowering agents, as a "Triple Pill" strategy on top of standard of care for the prevention of recurrent stroke in patients with a history of ICH and high normal or low grade hypertension. The study is a large-scale, international, double-blind, placebo-controlled, randomised controlled trial.
Intracerebral haemorrhage (ICH) is the most serious and least treatable form of stroke, accounting for at least 10% of the 20 million new strokes that occur globally each year. Survivors of ICH are at high risk of recurrent ICH and other serious cardiovascular events.
While there is strong evidence that this risk can be reduced by lowering the blood pressure (BP) of patients after ICH, many patients with ICH do not receive BP-lowering treatment long-term unless BP levels are particularly high, and many do not receive BP combination therapy.
The aim of this study is to assess the safety and efficacy of a combination of fixed low-dose generic BP lowering agents, as a "Triple Pill" strategy on top of standard of care for the prevention of recurrent stroke in patients with a history of ICH and high normal or low grade hypertension. The study is a large-scale, international, double-blind, placebo-controlled, randomised controlled trial.
Status Flow
Change History
22 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Oct 2025 — Present [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
▶ Show 17 earlier versions
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Sep 2021 — May 2024 [monthly]
Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Aug 2020 — Oct 2020 [monthly]
Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE3
-
May 2020 — Jul 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE3
-
Aug 2019 — Mar 2020 [monthly]
Recruiting PHASE3
-
Nov 2018 — Aug 2019 [monthly]
Recruiting PHASE3
Phase: PHASE4 → PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE4
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE4
-
Oct 2017 — Mar 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jul 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE4
-
Feb 2017 — Jul 2017 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- The George Institute
- The University of New South Wales
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Birtinya, Australia , Botucatu, Brazil , Chiayi City, Taiwan , Colombo, Sri Lanka , Curitiba, Brazil , Edinburgh, United Kingdom , Exeter, United Kingdom , Fortaleza, Brazil , Galle, Sri Lanka , Gampaha, Sri Lanka and 42 more locations